We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently.

Since Donald Trump took office, the stock market has experienced a roller coaster ride. Nonetheless, despite concerns about tariffs, job cuts, policy changes, and geopolitical uncertainties, the broader market has risen by 1.46% year-to-date. Furthermore, equity strategists in a Reuters poll project that the broader market will finish the year 9% higher than its current level.

“Many analysts agree with this projection, arguing that the Trump administration’s policies won’t have long-term negative impacts on economic growth or inflation. Furthermore, Trump is often considered the most pro-stock market president in American history.

In addition, one factor that could support the bull market is the adoption of AI, which, according to Morgan Stanley’s Andrew Slimmon, could lead to a productivity boom similar to what happened with the Internet in the late 1990s. Slimmon also points out that investor behavior over the last few years seems similar to what it was in previous bull markets, and adhering to these patterns can be one of the most reliable strategies for driving portfolio outperformance.

When analyzing investor behavior, we chose to focus on insiders—high-level executives and directors within a company. Why focus on insiders? Because they often have valuable insights into a company’s strategy, plans, and next moves. For example, when a CEO or CFO invests their own money in company shares, it can signal strong confidence in the company’s potential.

While both insider buying and selling can be driven by various motives, it’s important to consider these actions in the context of the company’s fundamentals, industry trends, and market conditions. This is why due diligence is crucial before making any investment. However, insider trading activity, along with other relevant factors, can offer valuable insights into a company’s capabilities, helping investors make more informed decisions.

What stocks have seen at least $10 million in insider spending recently? To find out, we used Insider Monkey’s insider trading stock screener, focusing on stocks where at least one insider purchase since the beginning of the year was valued at $10 million or more. Although the total value of insider purchases during this period may be higher, only those worth $10 million or more were considered in this search. Since there were more than 10 stocks meeting this criteria, we selected the 10 stocks with insider purchases ranging from $10 million to $20 million, choosing those with the highest amounts within this range for further analysis.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

For each stock, we provide details on the highest individual purchase, the number of insider purchases between $10 million and $20 million since the start of the year, and the company’s current market capitalization.

Metsera, Inc. (NASDAQ:MTSR)

Highest Individual Purchase: $14,219,964.00

Number of Purchases Worth Between $10 million and $20 million: 3

Market Capitalization: $2.55 billion

The eighth stock on this list of 10 stocks with at least $10 million in insider spending recently is a clinical-stage biotechnology company. Metsera, Inc. (NASDAQ:MTSR) focuses on developing injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. The New York City-based company is advancing its broad portfolio of therapies with the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.

On February 3rd, three insiders acquired a total of $94.22 million in Metsera shares at $18 per share during the company’s initial public offering. The company raised $257 million during its IPO, pricing shares above its targeted range. Of the five purchases, three were valued at $14.22 million each. The stock is currently trading at $24.78.

In January, the company shared promising results from a 12-week Phase 2a clinical trial of its leading candidate, MET-097i, a potential once-monthly injectable treatment for obesity. The data showed that MET-097i helped participants achieve significant weight loss, with some losing up to 20% of their body weight, and it was generally well tolerated, with only mild side effects. The company is planning additional studies in 2025.

According to data from StockAnalysis, four analysts have given Metsera stock an average ‘Strong Buy’ rating, with a price target of $47.

Metsera, Inc. (NASDAQ:MTSR) is also one of 10 stocks insiders spent the most money on recently.

Overall, MTSR ranks 8th on our list of stocks with at least $10 million in insider spending recently. While we acknowledge the potential of MTSR, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MTSR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.